Skip to main content

Table 3 Antibiotic-resistance profile of MDR strains and AgNPs susceptibility test

From: Enzyme-mediated formulation of stable elliptical silver nanoparticles tested against clinical pathogens and MDR bacteria and development of antimicrobial surgical thread

Bacteria Tested antibiotics Disk content (µg) ZOI (mm) Antibiotics susceptibility interpretationa
ESBL+ve E. coli Nalidixic acid 30 6.0 ± 0.50 R
Doxycycline 30 16.16 ± 0.28 S
Norfloxacin 10 8.0 ± 0.50 R
Nitrofurantoin 30 15.0 ± 0.50 I
Cefixime 30 6.0 ± 0.50 R
Cefixime/clavulanate 5/10 8.0 ± 0.50 R
Cefoperazone 75 6.0 ± 0.0 R
Cefoperazone/tazobactam 75/10 19.5 ± 1.0 S
Ceftazidime 30 7.0 ± 1.0 R
Cetazidime/clavulanate 30/10 14.0 ± 0.0 I
Chloramphenicol 30 15.16 ± 0.28 I
Cefprozil 30 6.5 ± 0.50 R
Cefepime 30 10.5 ± 0.50 R
AgNPs 2.16b 10.5 ± 0.50
AgNO3 3.4 9.16 ± 0.28
Sterile H2O 20 µl 0 ± 0
S. aureus (MRSA) Oxacillin 1 6.66 ± 0.28 R
Cefoxitin 30 19.33 ± 0.57 R
AgNPs 2.16b 13.5 ± 0.5
AgNO3 3.4 11.0 ± 0.0
Sterile H2O 20 µl 0 ± 0
S. pneumoniae MDR Teicoplanin 30 10.0 ± 0.0 R
AgNPs 2.16b 13.16 ± 0.28
AgNO3 3.4 11.0 ± 0.0
Sterile H2O 20 µl 0 ± 0
  1. All experiments were performed in triplicate
  2. R resistant, I intermediate, S susceptible
  3. aThe antibiotics susceptibility interpretation was based on CLSI guideline-2016
  4. b20 μl of 1 mM AgNO3 (MW 169.87) contains 3.4 μg AgNO3 and the percentage of silver is 63.5% in nanoparticles (i. e 2.16 μg)
\